HENGRUI PHARMA

1276
48.9600.73% ( -0.360 )
Delay Closed: Nov 16, 16:08:11

Overview

HENGRUI PHARMA (1276)

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical ne...

Open
49.360
High
49.980
Low
48.460
Prev. Close
49.320
Volume
2.36M
Turnover
115.54M
Avg Price
48.921
Bid/Ask Ratio
-94.39%
Amplitude
3.08%
52wk High
80.722
Volume Ratio
0.59
Turnover Ratio
0.91%
52wk Low
43.020
HK Mkt Cap
12.64B
Market CapHKD
324.96B
P/ETTM
31.40
P/EDynamic
30.22
P/EStatic
--
EPSTTM
1.56
EPSDynamic
1.62
EPSStatic
--
BVPS
11.73
P/B
4.17
HK Shares
258.20M
Dividend YieldTTM
0.47%
DividendTTM
0.228
Shares
6.64B
Min lot size
200
Currency
HKD

HENGRUI PHARMA Analyst Rating

View more

Forecast & Rating

Nov 13, 2026
Price forecast
HK$77.5358.35%
Forecast & RatingStrong buy
11analysts
  • Strong buy72.73%
  • Buy27.27%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Oct, 28

    Driven by an 89% year-on-year jump in Q3 net profit to RMB2.46bn, a 21% rise in revenue to RMB8.95bn, innovative drugs reaching nearly 65% of revenue and recognition of out-licensing income, Hengrui Pharma H-shares opened higher and extended gains in the Hong Kong morning session, last at HK$49.04 at 09:31 BJ, up 9.66% from the previous close of HK$44.72, with an intraday range of HK$45.98-49.20 and turnover of about HK$21.8m. The opening print was HK$46.00, and the session high of HK$49.20 marked a 10.02% advance from the previous close. The stock now sits above its MA20 of HK$47.95 and MA60 of HK$48.80, yet remains down 33.82% year-to-date, 39.68% below its 52-week high of HK$81.30 and 13.99% above its 52-week low of HK$43.02; market capitalisation is HK$324.8bn, with PE at 31.39x and PB at 4.17x. Though JPMorgan reduced its long position in the H-shares, the price is still nearly 40% below the 52-week high.

  2. Oct, 27

    Hengrui Pharma opened higher but reversed to close down 5.09% at HK$44.74 on HK$207.7 million turnover, sliding from an intraday HK$47.88 high to HK$44.28 as news that the US plans to restrict biotech investments weighed on China innovative-drug out-licensing sentiment, while Q2 revenue of HK$8.45 billion fell 9.77% year on year, net profit of HK$2.52 billion fell 10.57% and operating profit dropped 32.38%, a sharp reversal from Q1's 19.82% revenue growth and 29.16% net-profit growth. Even with clinical-trial approvals for SHR-2005 injection and two other drugs, Phase III HER2-low breast-cancer data for Ruikang trastuzumab and a share buyback, the stock remains below its MA20 of HK$47.72 and MA60 of HK$48.93, down 39.62% YTD, 45.9% below the 52-week high of HK$82.70 and only 4% above the 52-week low of HK$43.02. At a HK$296.9 billion market cap, PE 33.38x and PB 4.00x, the multiple has not de-rated in line with the share price, though buybacks and clinical progress provide some counterweight to the earnings slowdown.

  3. Sep, 30

    Shares of Hengrui Medicine surged 10.1% on Tuesday, fueled by a licensing agreement with Novo Nordisk for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, with the deal valued at up to $2.6 billion. The stock staged a rebound after dipping to HKD 45.44 at the opening, climbing steadily through both morning and afternoon sessions to an intraday high of HKD 50.40 before closing at HKD 50.20 on heavy volume. Despite Q2 revenue of HKD 8.44 billion, down 9.84% year-over-year, and operating profit falling 32.43%, the stock remains 16.69% above its 52-week low. However, it is still down 32.25% year-to-date and trades below its 60-day moving average of HKD 51.70. Though Q2 net profit declined 10.64% year-over-year, suggesting near-term fundamental pressure, the licensing news continues to dominate sentiment. The deal with Novo Nordisk includes an upfront payment and milestones, reinforcing Hengrui's global pipeline progress amid domestic pressure on Chinese pharma.

  4. Sep, 29

    1276.HK closed up 1.88% at HK$45.60 as Novo Nordisk signed an exclusive licence agreement with Hengrui for the once-weekly oral GLP-1/GIP dual agonist HRS-1596, with AstraZeneca and Merck's China biotech licensing deals also lifting sentiment. The tape showed a spike-and-fade: after touching the session high of HK$47.12 at 13:04 BJ, the stock slipped to HK$45.52 at 15:46 and settled at HK$45.60 on HK$255mn turnover. Fundamentals cut both ways — Q1 2026 revenue and net profit rose 19.6% and 28.92% yoy, while Q2 fell 9.84% and 10.64%, with operating profit down 32.43% and net margin at 29.85%. The price sits weak: down 38.46% YTD, 52.1% below the 52-week high of HK$95.2 and only 6% above the 52-week low of HK$43.02, still under the MA20 of HK$45.758 and MA60 of HK$51.846. Though its first A-share buyback has already exceeded RMB14.5mn.

  5. Sep, 21

    Hengrui Pharma surged 6.9% to close at HKD49.46 today, driven by positive policy signals for innovative drugs and the company's first A-share buyback of over RMB14.5 million. The stock staged a V-shaped recovery, hitting an intraday low of HKD46.88 in early morning trade before climbing steadily to the session high at close, with total turnover reaching HKD415 million. Citi noted the pharma industry's 15th Five-Year Plan favors innovative drugs, while several brokers maintained Buy ratings. However, the stock remains 33.25% down YTD and 48.05% below its 52-week high of HKD95.20; Q2 revenue fell 9.84% YoY and net profit dropped 10.64% YoY, underscoring lingering fundamental headwinds. At a P/E of 36.9x and P/B of 4.42x, valuation remains a point of contention.

News

Bullish vs. Bearish — Last 3 Months

23.2k followers · 0 opinions
▲Bullish50%
50%Bearish▼